Novavax announced that the Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use of the European Medicines Agency. The European Commission will review the CHMP recommendation and is expected to make a final decision in the coming days, the company said in a statement. “Following the positive CHMP opinion and pending European Commission decision, Novavax will work closely with EU member states on our shared goal of delivering an updated protein-based non-mRNA COVID-19 vaccine in Europe,” said John Jacobs, CEO of Novavax.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVAX:
- Largest borrow rate increases among liquid names
- NVAX Upcoming Earnings Report: What to Expect?
- Novavax receives full marketing approval for Nuvaxovid in UK
- Novavax’s prototype COVID-19 vaccine Nuvaxovid receives approval in Singapore
- Novavax remains ‘confident’ in rollout of updated COVID-19 vaccine in U.S.